Skip to content

Dolutegravir

Dolutegravir is an HIV integrase inhibitor. It blocks an enzyme HIV needs to insert viral genetic material into human cells. Tivicay contains dolutegravir alone, while Viropil combines it with two reverse transcriptase inhibitors.

Tivicay

Human Immunodeficiency Virus 1 (hiv-1) Infection

50mg

Formulated to alleviate retroviral disease to support immune preservation and target viral integrase enzymes.

From$8.18/ tabletView

Viropil

Human Immunodeficiency Virus 1 (hiv-1) Infection

50mg + 300mg + 300mg

Indicated to address retroviral duplication to manage HIV disease and alleviate risk of viral progression.

From$8.88/ tabletView

Key points

  • Dolutegravir belongs to the integrase inhibitor class.
  • Tivicay is the attached single-ingredient 50 mg tablet.
  • Viropil also contains lamivudine and tenofovir disoproxil.
  • Antacid and mineral timing can materially affect dolutegravir absorption.

Tivicay isolates the integrase inhibitor

Tivicay represents a 50 mg dolutegravir tablet. Like Viropil, it connects with HIV-1 infection in HIV management.

Dolutegravir reduces HIV in the blood when used as part of an antiretroviral regimen. It is not a complete HIV regimen simply because the catalogue record itself has one active ingredient.

Viropil places three classes in one tablet

Viropil contains dolutegravir, lamivudine and tenofovir disoproxil. Lamivudine and tenofovir are nucleoside or nucleotide reverse transcriptase inhibitors. The three-ingredient record therefore acts at two different stages of HIV replication.

Aluminium- or magnesium-containing antacids and products containing calcium or iron can reduce dolutegravir absorption unless product-specific timing instructions are followed. Consistent antiretroviral use matters because interruptions can allow viral resistance to emerge. Hypersensitivity reactions, liver symptoms and immune reconstitution effects are other important points in official information.

Further reading